essential information

Terms and conditions associated with the VIA programme.

financialBACK TO TOP

IADDITIONAL FUNDING
Applicable projects are not permitted to receive additional funding from other pharmaceutical companies or for-profit entities. Funding from non-profit entities may be permitted; please clearly state the entity, the nature of the funding and the amount of funding provided in your proposal.
IIAUTHORISED EXPENSES
The following expenses will be permitted:
  • Grant for hours of work necessary for the implementation of the project
  • Supplies and consumables necessary to fulfil the project's aims
  • Travel expenses directly related to the implementation of the project
  • Costs associated with the publication of the research
  • Up to 20% of overheads to the extent necessary to cover the expenses not specified above
IIIUNAUTHORISED EXPENSES
The following expenses listed below will not be permitted (but are not limited to):
  • Salary support outside of the hours required for the implementation of the project
  • Travel and/or housing related to sabbaticals
  • Purchase or rental of office equipment
  • Fees for tuition
  • Membership dues, congress/meeting registrations, subscriptions, books or journals.
IVFUNDS AND FINANCIAL REPORTS

A contract will be agreed between Vertex and the grant recipient centre and all grant recipients are required to submit a statement from their institution stating that the grant has been received. In the event that unexpended funds remain at the end of the funding period, these funds must be returned to the VIA programme.


A final financial report will be due 60 days after the end of the funding period reconciling the proposed budget with the actual expenditure.


The VIA Committee will be responsible for the selection and evaluation of the project, while Vertex will be responsible for payment and contractual matters with the project centre.

VDISBURSEMENT OF FUNDS

Payment of the VIA award will be made in instalments aligned with pre-agreed project milestones, and documented in your VIA award contract. All milestones must be supported by the submission, and subsequent committee approval of interim / final reports.

VIMULTIPLE GRANTS
Applicants may only receive one grant from the VIA programme per annual cycle.
VIIMULTIPLE APPLICATIONS FROM THE SAME INSTITUTION
More than one application from the same institution (i.e. university, hospital) is permitted. However, multiple applications from the same group of researchers at such an institute (i.e. those working in the same laboratory or department) are not permitted.
VIIIMULTI-CENTRE APPLICATIONS
Applications for multi-centre projects are permitted, but where this is the case a lead centre must be nominated. The application should be submitted by the principal investigator centre.
IXCHANGE IN GRANT RECIPIENT’S STATUS
The transfer of a grant to another institution will be at the sole discretion of the VIA programme and a new contract with the centre may be required.
XPROGRESS AND FINAL REPORTS
Project milestones are requested as part of the application process and will be documented in your VIA award contract. Interim progress reports and a final report at the end of the project, must be submitted for approval at these pre-agreed project milestones. Subsequent payments of the VIA award will then be made upon approval of the report and receipt of a satisfactory invoice.
XITERMINATION OF SUPPORT
If the grant recipient fails to comply with any terms of the agreement then Vertex reserves the right to deny funding and/or request return of funds, if paid.

commercialBACK TO TOP

IFOR-PROFIT ORGANISATIONS

For-profit organisations are not allowed to apply to the VIA programme (e.g. pharmaceutical companies, homecare companies, health maintenance organisations, etc.). The exceptions are research laboratories and academic institutions that may exist as part of a hospital that is run for profit.


If in doubt about eligibility, candidates should contact the VIA Secretariat who will provide guidance.

IICOMMERCIALISATION RIGHTS
Vertex may ask for a right of first refusal to obtain an exclusive worldwide license to any technology invented or improved under the grant. In such cases, Vertex will negotiate with the appropriate party to seek an appropriate arrangement.

otherBACK TO TOP

IRECOMBINANT MOLECULES, ANIMAL AND HUMAN SUBJECTS

Applicants requesting a grant to carry out research with recombinant molecules and/or animal or human subjects must obtain and show proof of the required approvals from the centre, local or government authority. If an applicant's institute does not require special permission for using recombinant molecules, then this must be communicated to the VIA Secretariat. Vertex can provide assistance with this process if requested by the investigator.


The VIA Secretariat must receive copies of appropriate permissions before any grant funds will be disbursed.


The applicant's institution has responsibility for ensuring that the rights of any human subjects are upheld and that animals are cared for in a humane manner.

IIPUBLICATIONS

The VIA programme strongly encourages the grant recipients to publish work carried out under a grant. This includes abstract submissions to congresses. Where a publication is not granted, proof of application is sufficient demonstration. An effort for publication submission must be shown.


Grant recipients must acknowledge the receipt of funding from the VIA programme in publications and abstracts describing research conducted with awards made by the VIA programme.

contact us

contact us

Should you have any queries regarding the VIA programme or the process of submitting a proposal, please contact the VIA Secretariat at the email below.

EMAIL: viasecretariat@chameleon-uk.com


Please note that the information you submit will be processed by Vertex and its global affiliates for appropriate use relating to VIA or as necessary to comply with Vertex's legal obligations, as further described in the Vertex Privacy Notice, which can be found at www.vrtx.com/international-privacy.